STEVENS PHARMA
ActiveSummary
STEVENS PHARMA has been active since 1990 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €324,659 and a net result of €39,269. Equity remains stable across the filed financial years (±0.2% per year). Its solvency ranks better than 89% of 5,014 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
13-07
NBB filing
Annual accounts filed
financial year 2025 · full format
2025
31-12
Financial
Highest result from 2018 to 2025net €39,269 ▲65.5%
Operating result €55,287, net result €39,269, both a record.
07-07
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
2024
29-08
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format · 29 days late
2023
31-08
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format · 31 days late
2022
31-08
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format · 31 days late
2021
31-12
Financial
Weakest financial yearnet €5,991 ▼75.5%
Net result drops to €5,991, the lowest in the series; recovery starts the following year.
18-08
NBB filing
Annual accounts filed
financial year 2020 · abbreviated format · 18 days late
2020
16-12
NBB filing
Annual accounts filed
financial year 2019 · abbreviated format · 138 days late
2019
04-07
NBB filing
Annual accounts filed
financial year 2018 · abbreviated format
2018
29-06
NBB filing
Annual accounts filed
financial year 2017 · abbreviated format
2017
24-07
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 35 annual accounts filed, the latest 10 are here; all 35 are under Financials.
0 of 4 deeds read
About the unread acts
We know of 4 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.